Abstract: SA-PO1129
Symptoms and Impacts Experienced by People Living with Nondiabetic CKD (ndCKD) and Diabetic Kidney Disease (DKD): Qualitative Interview Findings
Session Information
- CKD: Patient-Oriented Care and Case Reports
October 26, 2024 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 2302 CKD (Non-Dialysis): Clinical, Outcomes, and Trials
Authors
- Tadesse Bell, Sara, Genentech Inc, South San Francisco, California, United States
- Stein, Julia, Adelphi Values Ltd, Bollington, United Kingdom
- Ayala-Nunes, Lara, Adelphi Values Ltd, Bollington, United Kingdom
- Scouler, Eleanor, Adelphi Values Ltd, Bollington, United Kingdom
- Tatlock, Sophi, Adelphi Values Ltd, Bollington, United Kingdom
- Corey-Lisle, Patricia, Formerly Genentech Inc, San Francisco, California, United States
- Randhawa, Sharan, Adelphi Values Ltd, Bollington, United Kingdom
Background
The congruence of the non-diabetic chronic kidney disease (ndCKD) and diabetic kidney disease (DKD) patient experience is not well-known. This study aimed to compare/contrast symptoms and health-related quality-of-life [HRQoL] impacts reported by ndCKD and DKD patients to provide initial insights as to whether a consistent patient-reported outcome (PRO) measurement strategy could be applied across both populations in clinical trials.
Methods
Semi-structured, concept elicitation interviews were conducted to explore patients’ experiences of ndCKD/DKD. Interviews were audio recorded and verbatim transcripts were subject to thematic analysis in ATLAS.ti. Concepts identified were compared to explore similarities/differences in the patient experience of ndCKD and DKD.
Results
The sample was racially and ethnically diverse, comprising 24 participants (n=12 ndCKD [83.3% female]; n=12 DKD [66.7% female]), across CKD stages 2-5 and mean age 57 years (range 28-84). Almost all symptoms and impacts elicited were reported across both samples, though frequency of elicitation varied. Most participants (ndCKD n≥10/12; DKD n≥11/12) reported fatigue, low energy or weakness, frequent urination, swelling and nocturia. Erectile dysfunction (ED) was only reported in the DKD sample (n=2/12), which had a higher proportion of males. Restless legs was only reported in the ndCKD sample (n=1/12). Difficulty urinating, weight changes, gastrointestinal symptoms, and vision problems were reported by more DKD participants (n≥3). Muscle cramps were reported more frequently by ndCKD participants (n≥3). HRQoL impact reports were broadly comparable; impacts on diet/drinking were reported by more DKD participants (n≥3). All participants described emotional wellbeing impacts, and most (≥22/24) reported disruptions to daily activities and sleep. Other impacts included physical and social functioning, work and cognition.
Conclusion
Apart from ED and restless legs, all concepts were reported across both samples with small differences in elicitation frequency. Fatigue, frequent urination, swelling and nocturia were most frequently reported across both samples. Patients were also aligned on HRQoL impacts, suggesting that using the same PRO strategy in ndCKD/DKD may be appropriate, depending on the concepts of interest.
Funding
- Commercial Support – This study was funded by Genentech, Inc., a member of the Roche Group